66962-77-4

Upstream product

• 55779-06-1 fortimicin A 
• 54783-95-8 fortimicin B 
• 66962-56-9 1,2',6',2''-tetra-N-benzyloxycarbonyl-4-N-methyl-fortimicin A 
• 66962-55-8 1,2',6'-tri-N-(benzyloxycarbonyl)fortimicin B 
• 66962-59-2 [(2R,3R,6S)-2-((1R,2S,3S,4R,5S,6R)-2-Benzyloxycarbonylamino-5-{[2-(2-benzyloxycarbonylamino-acetylamino)-acetyl]-methyl-amino}-3,6-dihydroxy-4-methoxy-cyclohexyloxy)-6-(1-benzyloxycarbonylamino-ethyl)-tetrahydro-pyran-3-yl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

4-N-acylfortimicins B and the preparation of fortimicin A from fortimicin B.

Selective 4-N-acylation of fortimicin B (2) has been accomplished by 4-N-acylation of 1,2',6'-tri-N-benzyloxycarbonylfortimicin B (4) followed by hydrogenolysis of the N-protecting benzyloxycarbonyl groups. In this manner, fortimicin B was converted into fortimicin A (1), and a series of 4-N-acylfortimicins B (3) was prepared for antibacterial assay. The key intermediate, 1,2',6'-tri-N-benzyloxycarbonylfortimicin B, was prepared either directly from fortimicin B or by converting fortimicin A into 1,2',6',2''-tetra-N-benzyloxycarbonylfortimicin A (6a), followed by selective hydrolysis of the 4-N-(N-benzyloxycarbonyl)glycyl group of the latter.